LJFMarch30thClean Revised Perspectives for SRO.pdf (629.31 kB)
Patient-reported outcomes in metastatic castration-resistant prostate cancer
journal contribution
posted on 2023-06-09, 02:08 authored by Lesley FallowfieldLesley Fallowfield, Heather Payne, Valerie JenkinsValerie JenkinsMany novel therapies are available for use in patients with metastatic castration-resistant prostate cancer (mCRPC), some of which convey substantial progression-free survival and overall survival benefits. Delaying disease progression and providing palliation of symptoms are primary therapeutic aims of treating patients with mCRPC; therefore, ensuring that the benefit-to-harm ratios are acceptable to patients, through systematic measurement of patient-reported outcomes (PROs) using validated tools, is vital. In this Perspectives, we appraised the published reports from clinical trials testing treatments of mCRPC over the past 5 years and found that PROs were either not being measured routinely, or if used, were often not reported adequately, thus hampering evaluation of the true effects of many of these treatments on patients' quality of life. Improvements are needed because data collected directly from patients, not just physician-collected safety data and adverse events, are crucial to inform clinical decision-making on treatment options.
History
Publication status
- Published
File Version
- Accepted version
Journal
Nature Reviews Clinical OncologyISSN
1759-4774Publisher
Macmillan Publishers LimitedExternal DOI
Issue
10Volume
13Page range
643-650Department affiliated with
- Sussex Health Outcomes Research & Education in Cancer (SHORE-C) Publications
Full text available
- Yes
Peer reviewed?
- Yes
Legacy Posted Date
2016-07-12First Open Access (FOA) Date
2016-12-29First Compliant Deposit (FCD) Date
2016-07-12Usage metrics
Categories
No categories selectedLicence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC